Novartis AG

NVS Healthcare Drug Manufacturers General

Novartis AG’s revenue for fiscal 2025 (year ended December 2025) was $56.7 billion, up 9.57% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS fell 17.4%, free cash flow fell 15.5% and total debt rose 52.9%, each against the same quarter a year earlier. Dividend growth for five consecutive years, revenue growth for three, operating cash flow growth for three.

150.62 0.24 +0.16%
Market cap
$275.3B
P/E
22.6×
Fwd P/E
20.6×
Dividend yield
3.15%
F-score
8/9
Altman Z
4.13
Beneish M
−2.49
Dividend safety
66/100

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Total current assets
27,351.00 26,607.00 30,460.00 28,198.00
Total non-current assets
94,682.00 91,925.00 80,489.00 79,091.00
Total Assets
122,033.00 118,532.00 110,949.00 107,289.00
Total current liabilities
31,748.00 31,374.00 27,278.00 32,000.00
Total non-current liabilities
48,339.00 48,231.00 37,122.00 30,537.00
Total liabilities
80,087.00 79,605.00 64,400.00 62,537.00
Common Equity (Total)
41,946.00 38,927.00 46,549.00 44,752.00
Shareholders Equity (Total)
41,946.00 38,927.00 46,549.00 44,752.00
Total Debt
47,077.00 45,064.00 33,537.00 30,118.00

Show all line items

In millions of $ except per-share values · columns are period end dates